Monoclonal Antibodies Industry to Reach New Heights USD 647.01 Billion with a CAGR of 12% Through 2032

Monoclonal Antibodies Industry

The global monoclonal antibodies (mAbs) industry, valued at USD 186 billion in 2021, is anticipated to witness substantial growth, exhibiting a compound annual growth rate (CAGR) of 12% during the forecast period from 2022 to 2032. This growth trajectory highlights the increasing significance of mAb therapies in the treatment of chronic and life-threatening diseases.

Key Growth Drivers:

1. Rising Prevalence of Chronic Diseases:
   • The global burden of conditions such as cancer, cardiovascular diseases, autoimmune disorders, and infectious diseases has led to an increased demand for advanced biologics. Monoclonal antibodies provide targeted, effective solutions with reduced side effects, making them an essential tool in modern medicine.
2. Expansion of Targeted Therapies:
   • Monoclonal antibody therapies offer precision treatment, targeting specific proteins and pathways involved in disease progression. This has made them a preferred choice for personalized medicine in oncology, immunology, and rare diseases.
3. Growing Awareness Among Stakeholders:
   • Awareness campaigns and medical education initiatives have enhanced the understanding of the efficacy and benefits of mAb therapies among patients, healthcare providers, and policymakers.
4. Technological Advancements:
   • Innovations in antibody engineering, including bispecific antibodies, antibody-drug conjugates (ADCs), and next-generation mAbs, are driving market expansion.

A Full Report Analysis – https://www.futuremarketinsights.com/reports/monoclonal-antibodies-market

Market Outlook:

The monoclonal antibodies market is poised for transformative growth, with increasing investment in R&D, regulatory support for biologics, and expanded access to advanced therapies in emerging markets. As a result, the industry is expected to remain a cornerstone of the global biopharmaceutical sector for years to come.

2017-2021 Monoclonal Antibodies Demand Analysis vs. Forecast 2022-2032

The global demand for Monoclonal Antibodies is projected to increase at a CAGR of 12% during the forecast period between 2022 and 2032, reaching a total of US$ 647.01 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6.1%.

Human mAbs offer efficient modulation in effector functions and are less immunogenic as compared to chimeric or humanized mAbs. Such antibodies can be produced through the use of phage display and hybridoma technologies in transgenic mice. As a result, with recent technological progress in genetic engineering, the production of fully human mAbs is anticipated to gain traction in the near future.

Humanized mAbs are expected to reveal the fastest CAGR in the forecast period due to their widespread use against a broad range of target antigens such as cancer cells, immunosuppression, and immunomodulatory molecules. Demand for such antibodies is also supported by their lower immunogenicity as compared to chimeric mAbs. However, these antibodies are more immunogenic as compared to human mAbs, which may restrict the market growth

Market Competition

Key players in the Monoclonal Antibodies market are Novartis AG; Pfizer Inc; GlaxoSmithKline plc; Amgen Inc.; Merck & Co., Inc.; Daiichi Sankyo Company, Limited; Abbott Laboratories; AstraZeneca plc; Eli Lilly And Company; Johnson & Johnson Services, Inc. and many more.

• In November 2021, Bristol-Myers Squibb Company received the US Food and Drug Administration approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer. Patients with squamous or non-squamous illness, independent of PD-L1 expression, are eligible for the treatment. 1 The FDA’s Real-Time Oncology Examine (RTOR) pilot program was used to review this application, which aims to ensure that safe and effective medicines are offered to patients as soon as feasible.

• In March 2022, Sanofi S.A. and Blackstone Life Sciences entered a collaboration for accelerating the development of a subcutaneous formulation of Sarclisa mAb for the treatment of patients with multiple myeloma.

Key Companies Profiled

• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline Plc.
• Amgen Inc.
• Merck & Co. Inc.
• Daiichi Sankyo Company Limited
• Abbott Laboratories
• AstraZeneca Plc.
• Eli Lilly & Company
• Johnson & Johnson Services Inc.
• Bayer AG
• Bristol Myers Squibb
• F. Hoffman-La Roche Ltd.
• Viatris Inc.
• Biogen Inc.
• Thermo Fisher Scientific Inc.
• Novo Nordisk A/S
• Sanofi S.A.

Key Segments Profiled in the Monoclonal Antibodies Market Industry Survey

Monoclonal Antibodies Market by Production Type:

• In Vivo
• In Vitro

Monoclonal Antibodies Market by Source Type:

• Murine
• Chimeric
• Humanized
• Human

Monoclonal Antibodies Market by End User:

• Hospitals
• Specialty Centers
• Others

Monoclonal Antibodies Market by Application:

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Neurological Diseases
• Others

Monoclonal Antibodies Market by Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube